CL2019003015A1 - Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. - Google Patents

Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.

Info

Publication number
CL2019003015A1
CL2019003015A1 CL2019003015A CL2019003015A CL2019003015A1 CL 2019003015 A1 CL2019003015 A1 CL 2019003015A1 CL 2019003015 A CL2019003015 A CL 2019003015A CL 2019003015 A CL2019003015 A CL 2019003015A CL 2019003015 A1 CL2019003015 A1 CL 2019003015A1
Authority
CL
Chile
Prior art keywords
ahr
inhibitors
aryl hydrocarbon
hydrocarbon receptor
indole aryl
Prior art date
Application number
CL2019003015A
Other languages
English (en)
Inventor
Alfredo C Castro
Catherine Anne Evans
Original Assignee
Kyn Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyn Therapeutics filed Critical Kyn Therapeutics
Publication of CL2019003015A1 publication Critical patent/CL2019003015A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS ÚTILES COMO INHIBIDORES DE AHR, COMPOSICIONES DE LOS MISMOS Y MÉTODOS PARA USAR LOS MISMOS.
CL2019003015A 2017-04-21 2019-10-21 Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. CL2019003015A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488476P 2017-04-21 2017-04-21
US201762592542P 2017-11-30 2017-11-30
US201862658454P 2018-04-16 2018-04-16

Publications (1)

Publication Number Publication Date
CL2019003015A1 true CL2019003015A1 (es) 2020-03-27

Family

ID=63856153

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003015A CL2019003015A1 (es) 2017-04-21 2019-10-21 Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.

Country Status (14)

Country Link
US (4) US10570138B2 (es)
EP (1) EP3612030A4 (es)
JP (2) JP7232244B2 (es)
CN (1) CN110831600B (es)
AU (1) AU2018256459B2 (es)
BR (1) BR112019021992A2 (es)
CA (1) CA3059939A1 (es)
CL (1) CL2019003015A1 (es)
CO (1) CO2019011584A2 (es)
IL (1) IL270025B2 (es)
MX (1) MX2019012431A (es)
SG (1) SG11201909710XA (es)
TW (1) TWI778050B (es)
WO (1) WO2018195397A2 (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10981911B2 (en) 2016-12-16 2021-04-20 Janssen Pharmaceutica Nv Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
US11059823B2 (en) 2016-12-16 2021-07-13 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US11066406B2 (en) 2018-06-15 2021-07-20 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3612030A4 (en) 2017-04-21 2021-04-28 Ikena Oncology, Inc. AHR INDOLE INHIBITORS AND THEIR USES
FR3066761B1 (fr) 2017-05-23 2020-10-30 Centre Nat Rech Scient Nouveaux composes inhibiteurs des canaux ioniques
AU2018319016B2 (en) 2017-08-17 2023-08-31 Ikena Oncology, Inc. AHR inhibitors and uses thereof
JP7382348B2 (ja) 2018-02-06 2023-11-16 アイディアヤ バイオサイエンシーズ，インコーポレイティド ＡｈＲモジュレータ
WO2019156989A1 (en) * 2018-02-06 2019-08-15 Ideaya Biosciences, Inc. COMPOUNDS AND METHODS FOR THE MODULATION OF AhR
EP3847176A1 (en) * 2018-09-07 2021-07-14 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compound
WO2020081636A1 (en) * 2018-10-16 2020-04-23 Ikena Oncology, Inc. Indole ahr inhibitors and uses thereof
US20210379033A1 (en) * 2018-10-17 2021-12-09 Magenta Therapeutics Inc. Methods of treating cancer with aryl hydrocarbon receptor antagonists
KR20210110797A (ko) * 2018-11-30 2021-09-09 셀룰래리티 인코포레이티드 조혈 줄기세포 및 전구세포의 활성화에 사용하기 위한 방향족 화합물
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
KR20210131316A (ko) * 2019-02-27 2021-11-02 밀레니엄 파머슈티컬스 인코퍼레이티드 Sumo-활성화 효소 저해제 및 관문 저해제의 투여
EP4003337A4 (en) * 2019-07-30 2023-06-28 Oregon State University Aryl hydrocarbon receptor activators
JP2023502476A (ja) * 2019-11-22 2023-01-24 センダ バイオサイエンシーズ， インコーポレイテッド Ａｈｒアンタゴニストとしてのピリドピリミジノン誘導体
CN115279764A (zh) 2019-11-26 2022-11-01 医肯纳肿瘤学公司 多晶型咔唑衍生物及其用途
MX2022005912A (es) * 2019-11-26 2022-06-24 Hoffmann La Roche Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria.
AU2020391451A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. AHR inhibitors and uses thereof
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
KR20220125323A (ko) 2020-01-10 2022-09-14 이케나 온콜로지, 인코포레이티드 Ahr 억제제 및 이의 용도
AU2021226411A1 (en) 2020-02-26 2022-09-22 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of AhR signalling
US20230150970A1 (en) * 2020-03-27 2023-05-18 Dong-A St Co., Ltd. Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
WO2022029063A1 (en) * 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
US20240148740A1 (en) 2020-10-28 2024-05-09 Ikena Oncology, Inc. Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
CN114644627A (zh) * 2020-12-18 2022-06-21 山东轩竹医药科技有限公司 AhR抑制剂及其用途
CN112656789A (zh) * 2020-12-31 2021-04-16 中国科学院生态环境研究中心 Ficz在抑制肿瘤细胞迁移中的应用
CN114805361B (zh) * 2021-01-17 2024-02-20 上海凌达生物医药有限公司 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN118076613A (zh) * 2021-09-02 2024-05-24 捷豹治疗有限公司 可用于调节AhR信号传导的化合物
WO2023033741A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
WO2023033742A1 (en) * 2021-09-02 2023-03-09 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
CN115093400B (zh) * 2021-09-18 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂及其用途和制备方法
WO2023060227A1 (en) 2021-10-07 2023-04-13 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN115925684A (zh) * 2021-12-03 2023-04-07 徐诺药业(南京)有限公司 一种嘧啶类衍生物及其制备方法和应用
WO2023135057A1 (en) 2022-01-11 2023-07-20 Deutsches Krebsforschungszentrum Bicyclic triazine derivatives for the treatment of cancer
CN117624168A (zh) * 2022-08-19 2024-03-01 德明药泰生物技术（深圳）有限公司 稠环杂环类化合物及其制备方法和应用
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
CN115804776A (zh) * 2022-12-16 2023-03-17 国纳之星(上海)纳米科技发展有限公司 一种芳香烃受体抑制剂和5-氟尿嘧啶合用在治疗抑制肿瘤药物中的应用
CN116482278B (zh) * 2023-05-06 2024-02-09 广州清瑞生物科技有限责任公司 一种用于检测阿昔洛韦的对照品的制备方法
CN117229284B (zh) * 2023-11-10 2024-02-06 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
MXPA03005393A (es) * 2000-12-19 2003-09-25 Merck Patent Gmbh Formulacion farmaceutica que contiene pirazolo (4,3-d) pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina.
US20040235877A1 (en) 2001-09-14 2004-11-25 Natsuki Ishizuka Novel use of tricyclic compound
US7078525B2 (en) * 2002-09-04 2006-07-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US6992080B2 (en) * 2002-09-19 2006-01-31 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
EP1814885A4 (en) * 2004-11-23 2009-12-16 Us Therapeutics Inc Reddy NOVEL HETEROCYCLIC BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
EP2343320B1 (en) 2005-03-25 2017-10-25 GITR, Inc. Anti-gitr antibodies and uses thereof
EP2559690B1 (en) 2005-05-10 2016-03-30 Incyte Holdings Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
WO2007075598A2 (en) 2005-12-20 2007-07-05 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP2064207B1 (en) 2006-09-19 2013-11-06 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP2086979B1 (en) * 2006-11-06 2015-06-03 Tolero Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN101932325B (zh) 2007-11-30 2014-05-28 新联基因公司 Ido抑制剂
EP2229390B1 (en) * 2007-12-14 2014-04-09 F. Hoffmann-La Roche AG Novel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives
WO2009156652A1 (fr) 2008-05-29 2009-12-30 Saint-Gobain Centre De Recherches Et D'etudes Europeen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9221910B2 (en) 2010-03-05 2015-12-29 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
CN102918060B (zh) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 抗人csf-1r抗体及其用途
SI2566517T1 (sl) 2010-05-04 2019-01-31 Five Prime Therapeutics, Inc. Protitelesa, ki vežejo CSF1R
EP2614082B1 (en) 2010-09-09 2018-10-03 Pfizer Inc 4-1bb binding molecules
EP2621926B1 (en) * 2010-09-30 2017-08-30 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde10 inhibitors
BR122021026169B1 (pt) 2010-12-09 2023-12-12 The Trustees Of The University Of Pennsylvania Uso de uma célula
NO2694640T3 (es) 2011-04-15 2018-03-17
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
BR112013026521A2 (pt) 2011-04-21 2016-12-27 Origenis Gmbh pirazolo[4,3-d]pirimidinas úteis como inibidores de cinase
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
CA2858069C (en) 2011-12-08 2020-02-11 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013087699A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CA2861122A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AR090650A1 (es) * 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
BR112014028013A2 (pt) 2012-05-11 2018-02-27 Five Prime Therapeutics Inc métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US20140079699A1 (en) 2012-08-31 2014-03-20 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9637491B2 (en) * 2012-10-19 2017-05-02 Origenis Gmbh Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
US10457683B2 (en) 2017-04-12 2019-10-29 Magenta Therapeutics Inc. Aryl hydrocarbon receptor antagonists and uses thereof
EP3612030A4 (en) 2017-04-21 2021-04-28 Ikena Oncology, Inc. AHR INDOLE INHIBITORS AND THEIR USES

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10981911B2 (en) 2016-12-16 2021-04-20 Janssen Pharmaceutica Nv Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
US11059823B2 (en) 2016-12-16 2021-07-13 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US11827638B2 (en) 2016-12-16 2023-11-28 Janssen Pharmaceutica Nv Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
US11066406B2 (en) 2018-06-15 2021-07-20 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
US11787807B2 (en) 2018-06-15 2023-10-17 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases

Also Published As

Publication number Publication date
BR112019021992A2 (pt) 2020-06-09
CA3059939A1 (en) 2018-10-25
EP3612030A4 (en) 2021-04-28
CN110831600B (zh) 2023-10-17
CN110831600A (zh) 2020-02-21
IL270025B1 (en) 2023-01-01
JP7232244B2 (ja) 2023-03-08
AU2018256459A1 (en) 2019-11-07
TWI778050B (zh) 2022-09-21
AU2018256459B2 (en) 2023-12-07
JP2022116319A (ja) 2022-08-09
MX2019012431A (es) 2020-08-03
EP3612030A2 (en) 2020-02-26
US20230028336A1 (en) 2023-01-26
TW201841917A (zh) 2018-12-01
IL270025A (es) 2019-12-31
KR20190141722A (ko) 2019-12-24
JP2020517734A (ja) 2020-06-18
IL270025B2 (en) 2023-05-01
WO2018195397A3 (en) 2018-12-13
CO2019011584A2 (es) 2020-02-18
SG11201909710XA (en) 2019-11-28
US10689388B1 (en) 2020-06-23
US11358969B2 (en) 2022-06-14
WO2018195397A2 (en) 2018-10-25
US20200331917A1 (en) 2020-10-22
US10570138B2 (en) 2020-02-25
US20180327411A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
CL2019003015A1 (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
CO2019004630A2 (es) Composiciones de células t con car anti-bcma
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
EA202190726A1 (ru) Индольные ингибиторы арил-гидрокарбонового рецептора (ahr) и их применение
MA47585A (fr) Composés modulateurs du récepteur des hydrocarbures aryle (ahr)
CY1120935T1 (el) Νεες συνθεσεις, χρησεις και μεθοδοι για την παρασκευη αυτων
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CL2020001546A1 (es) Compuestos de 4-azaindol.
ECSP17023281A (es) Inhibidores de mk2 y sus usos
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CL2018000696A1 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue.
CR20180058A (es) Nuevos derivados de fenoximetilo
GT201700231A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CR20150524A (es) Compuestos de heteroarilo y sus usos
MD3307271T2 (ro) Metode de utilizare a activatorilor de piruvat kinază
ECSP19055169A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
ECSP19055179A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CL2016002084A1 (es) Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.
CO2020015747A2 (es) Analogos de rapamicina y usos de los mismos
CL2021000296A1 (es) Inhibidores tipo indol y azaindol de enzimas pad.
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
ECSP16074207A (es) Pirazinas moduladoras de gpr6